Hepion to present positive CRV431 findings at liver conference

Hepion Pharmaceuticals

Hepion Pharmaceuticals (NASDAQ:HEPA) will present positive findings from an expanded study of CRV431 at The Liver Meeting Digital Experience 2020 on Nov. 13.

The poster presentation will review a study in which Hepion’s lead candidate, CRV431, prevented experimentally induced liver fibrosis to a greater extent than four other leading non-alcoholic steatohepatitis (NASH) drug candidates in a human precision cut liver slices experimental model.

“CRV431’s distinguishing factor from other NASH drug candidates is that it directly targets fibrotic scar formation by down-regulating cyclophilin B, an important regulator of collagen synthesis,” Daren Ure, Ph.D., Hepion’s CSO, said in a statement.  

“We look forward to discussing the study’s findings, which suggest that CRV431 has the potential to complement other therapies to decrease NASH-related liver fibrosis,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.